miniseriesThesis on AVDL: Maintaining a Buy Rating Q4 2023 Earnings and Commercial Performance of Lumryz We update readers based on FY 2023 earnings print and litigation update, where we carefully evaluated our thesis and decided to maintain our buy rating on AVDL (our latest analysis). Avadel Pharmaceuticals reported its Q4 2023 earnings, highlighting the commercial traction of Lumryz, its novel once-nightly formulation of sodium oxybate for narcolepsy. We believe the earnings are positive based on the ...